EF Hutton Acquisition Co. I reiterated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday morning, Benzinga reports. EF Hutton Acquisition Co. I currently has a $16.00 target price on the stock.
IPSC has been the topic of a number of other reports. SVB Leerink decreased their price objective on Century Therapeutics from $20.00 to $14.00 and set an outperform rating on the stock in a research report on Friday, January 6th. HC Wainwright reiterated a buy rating and issued a $19.00 price objective on shares of Century Therapeutics in a research report on Thursday, February 9th. Piper Sandler decreased their price objective on Century Therapeutics from $24.00 to $14.00 and set an overweight rating on the stock in a research report on Friday, January 6th. Finally, Chardan Capital started coverage on Century Therapeutics in a research report on Tuesday, December 27th. They issued a buy rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $19.00.
Century Therapeutics Price Performance
IPSC stock opened at $3.86 on Thursday. The business has a fifty day moving average price of $4.53 and a 200 day moving average price of $7.68. Century Therapeutics has a fifty-two week low of $3.54 and a fifty-two week high of $14.02. The company has a quick ratio of 13.44, a current ratio of 13.44 and a debt-to-equity ratio of 0.02.
Institutional Inflows and Outflows
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.